Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression

493 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019, background): “As we address in the forthcoming section, insight is also a core component of the psychedelic experience (Watts et al., 2017; Noorani et al., 2018).”
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression (2018, background): “…post-drug integration work (Frederking, 1955; Sandison, 1955; Abramson, 1956; Martin, 1957; Eisner and Cohen, 1958; Leuner, 1961; Jensen, 1963; Shagass and Bittle, 1967; Richards, 1978; Loizaga-Velder, 2013; Gasser et al., 2014; Belser et al., 2017; Russ and Elliott, 2017; Watts et al., 2017).”
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017, methodology): “Six-month follow-up interviews were carried out by RW with all 20 patients and the relevant qualitative data are reported elsewhere (Watts et al. 2017).”
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future (2017, background): “…via post-synaptic 5-HT1A receptor signaling (Cowen and Browning, 2015; Deakin and Graeff, 1991; McCabe et al, 2010); this contrasts with the greater role for 5-HT2AR signaling with psychedelics, and emphasis on emotional release (Carhart-Harris et al, 2012b; Roseman et al, 2016; Watts et al, 2017).”